Small-molecule adjuvants testing pipeline (Influenza)

承包商将确定可用于增强人类疫苗效力的新型佐剂候选物。根据该奖项进行的研究将有助于开发新的佐剂，这些佐剂可以：(a)利用先天免疫系统的自然能力来启动和维持有效的T细胞和B细胞反应，并诱导长期免疫记忆，或者(B)直接作用于适应性免疫系统的细胞，以增强它们对病原体来源抗原的反应。

The contractor will identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research performed under this award will contribute to the pipeline of new adjuvant leads that either: (a) exploit the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory, or (b) act directly on cells of the adaptive immune system to enhance their response to pathogen-derived antigens. Studies include testing of adjuvant candidates with experimental or FDA approved preventative or therapeutic vaccines in relevant animal models to determine the potential efficacy of the vaccine (including rHA influenza vaccine) against one or more pathogens relevant to human disease.